Modality
ASO
MOA
SOS1i
Target
AHR
Pathway
DDR
SMACLL
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
~Sep 2018
→ ~Dec 2019
Phase 2
Mar 2020
→ Apr 2030
Phase 2Current
NCT03445151
1,279 pts·CLL
2020-03→2027-02·Active
NCT07525990
879 pts·SMA
2025-09→2030-04·Recruiting
2,158 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-02-0210mo awayPh2 Data· CLL
2030-04-284.1y awayPh2 Data· SMA
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Active
P2
Recruit…
Catalysts
Ph2 Data
2027-02-02 · 10mo away
CLL
Ph2 Data
2030-04-28 · 4.1y away
SMA
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03445151 | Phase 2 | CLL | Active | 1279 | DAS28 |
| NCT07525990 | Phase 2 | SMA | Recruiting | 879 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| HAL-1232 | Halozyme | Approved | C5 |